Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.

Yokote K, Yamauchi T, Fukushima Y, Takatsuka Y, Kato M, Yan S, Inoue T, Borowska L, Brueckmann M, Ogawa W, SYNCHRONIZE‐JP Trial Investigators

Open source

DOI
10.1111/dom.70862
Published
2026 Aug
Container
Diabetes, obesity & metabolism
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/dom.70862,
  title = {Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.},
  author = {Yokote K and Yamauchi T and Fukushima Y and Takatsuka Y and Kato M and Yan S and Inoue T and Borowska L and Brueckmann M and Ogawa W and SYNCHRONIZE‐JP Trial Investigators},
  year = {2026},
  journal = {Diabetes, obesity \& metabolism},
  doi = {10.1111/dom.70862},
  url = {https://doi.org/10.1111/dom.70862}
}

RIS

TY  - JOUR
TI  - Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.
AU  - Yokote K
AU  - Yamauchi T
AU  - Fukushima Y
AU  - Takatsuka Y
AU  - Kato M
AU  - Yan S
AU  - Inoue T
AU  - Borowska L
AU  - Brueckmann M
AU  - Ogawa W
AU  - SYNCHRONIZE‐JP Trial Investigators
PY  - 2026
JO  - Diabetes, obesity & metabolism
DO  - 10.1111/dom.70862
UR  - https://doi.org/10.1111/dom.70862
ER  - 

APA

K, Y., T, Y., Y, F., Y, T., M, K., S, Y., T, I., L, B., M, B., W, O., & Investigators, S. T. (2026). Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70862

Source records